The biotech company embattled by activist investor VenBio may not be able to go through with its licensing deal.
This offering puts Valeant's debt at roughly $31 billion.
Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.
Could Oprah Winfrey herself take the helm at the diet company?
The company's shares continued to fall after news that the drug company will take on more debt.
The Laval, Quebec-based biotech announced that it would pay down $1.1 billion in debt Monday.
The scandals plaguing the pharmaceutical company can be traced to lack of change at the board level.
The pharma is gearing up to commericialize its lead drug, a treatment for lymphoma.
Forty states have now sued the companies.
The company also has a huge pile of debt hanging over its head.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.